Digital Pathology Market Size, Share, Growth Analysis, By Product (Software, Device, Storage Systems), By Type (Human pathology, Veterinary pathology), By End user (Pharmaceutical, Biotechnology), By Region - Industry Forecast 2024-2031

Global Digital Pathology Market size was valued at USD 1051.59 million in 2022 and is poised to grow from USD 1133.61 million in 2023 to USD 2067.36 million by 2031, at a CAGR of 7.8% during the forecast period (2024-2031).

The Global Digital Pathology Market is highly competitive, with a large number of players operating in the space. Some of the key players in the market are focused on product development and innovation, strategic partnerships and collaborations, and mergers and acquisitions to strengthen their market position. They are also investing heavily in research and development activities to develop advanced digital pathology solutions that offer improved accuracy, speed, and efficiency. In addition, companies are expanding their geographic reach by targeting emerging markets in Asia-Pacific and Latin America, which offer significant growth opportunities due to increasing healthcare expenditure and the rising prevalence of chronic diseases. Overall, the competitive landscape of the digital pathology market is expected to remain intense, with companies vying for a larger share of the rapidly growing market. 'Philips Healthcare (Netherlands) ', 'Roche Diagnostics (Switzerland) ', 'Hamamatsu Photonics (Japan) ', '3DHISTECH (Hungary) ', 'GE Healthcare (US) ', 'Apollo Enterprise Imaging (US) ', 'Olympus Corporation (Japan) ', 'Mikroscan Technologies (US) ', 'Inspirata (US) ', 'PerkinElmer (US) ', 'Huron Digital Pathology (Canada) ', 'Sectra AB (Sweden) ', 'PathAI (US) ', 'Indica Labs (US) ', 'F. Hoffmann-La Roche (Switzerland) ', 'Nikon Corporation (Japan) ', 'Danaher Corporation (US) ', 'Visiopharm (Denmark) ', 'Densitas (Canada) ', 'Objective Pathology (US) ', 'QPath (US)'

Continuous advancements in digital imaging technology, such as whole-slide imaging (WSI), high-resolution scanners, and image analysis software, are driving the adoption of digital pathology. These technological innovations offer improved image quality, faster scanning times, and enhanced analysis capabilities, leading to more accurate and efficient diagnoses. For example, the development of deep learning algorithms and artificial intelligence (AI) tools has enabled automated image analysis and detection of abnormalities in pathology slides, aiding pathologists in their decision-making process.

Telepathology and Remote Consultation: The increasing adoption of telepathology allows for remote diagnosis and consultation, enabling pathologists to collaborate and provide expert opinions regardless of geographical constraints. Telepathology has gained prominence during the COVID-19 pandemic, as it facilitates remote working and minimizes the risk of exposure for pathologists. For example, pathologists can remotely review and discuss cases with colleagues, participate in multidisciplinary tumor boards, or provide consultations to underserved areas or regions facing a shortage of pathology expertise.

In 2022, North America dominated the global digital pathology market. This can be attributed to various factors, including increasing government initiatives towards the development of technologically advanced pathologies, continual investments in research and development, rising adoption of digital imaging, and the presence of key market players in the region. For instance, PathAI launched AISight, a digital pathology platform in 13 leading health systems across the U.S. to participate in an Early Access Program. The increasing usage of digital pathology in academic research and disease diagnosis is also contributing to the growth of the regional market.